Robert Hodge joined COUR in 2023 as VP, Technical Development, where he oversees late-stage process and product development, analytics, and preparations for commercialization.
Prior to joining COUR, Robert had been a Principal Consultant at Therapartners since 2021. Before this, he served as VP, Technical Development, for AveXis, Inc., and at Novartis Gene Therapies after AveXis was acquired by Novartis in 2018. From 2012 to 2016, Robert was Director, Manufacturing Science and Technology, at Hospira and at Pfizer after it acquired Hospira in 2015. Before this, he was Senior Director, Manufacturing, at Kythera Biopharmaceuticals Inc from 2006 to 2012. From 1990 to 2005, Robert held various positions in manufacturing and development at Amgen Inc. Robert received a bachelor of science in chemical engineering from the University of California Santa Barbara.